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Summary 4, 6-0-Benzylidene-D-glucopyranose (BG), a derivative of benzaldehyde (BA), whose anti-tumour
action has often been reported, showed responses in 10 out of 24 patients (41.7%). These patients consisted of
11 cases of primary lung cancer, 4 of metastatic lung cancer, 5 of gastric cancer, and one each of cancer of the
sigmoid colon, liver, pancreas and prostate. There were two complete responses (one each of ipsilateral lung
metastasis from breast cancer and metastatic liver lesions due to gastric cancer). The mean total dose of BG
was 392.6 g, given by intravenous infusion of 1.2 g BG in 100 ml saline twice daily. The treatment was
discontinued when no response was observed after two months. Careful monitoring showed no toxic action of
BG at these large doses. Complete necrotic liquefaction of tumour, without any damage to surrounding tissue,
was seen in 2 of 3 cases in which histological examination was feasible. It is apparent that BG, like BA, is not
a cytotoxic agent in the ordinary sense, but its mechanism of action is still unknown.
The anti-tumour effects of various aldehydes have often been
reported (Osato, 1950; Conroy et al., 1975; Sessa et al., 1977;
Derin et al., 1978; Egyud & Gyorgyi, 1968). Among them,
the effects ofbenzaldehyde (BA), originally extracted from fig
fruit, on experimentally induced carcinomas (Takeuchi et al.,
1978; Petterson et al., 1985; Soga et al., 1985), on cultured
cell lines (Zundel et al., 1975; Miyakawa et al., 1979;
Watanuki & Sakaguchi, 1980; Watanuki & Sakaguchi, 1981;
Isida et al., 1983; Nambata et al., 1982; Petterson et al., 1983;
Petterson et al., 1983; Petterson et al., 1985) and on
advanced stage human carcinomas (Kochi et al., 1980; Kochi
et al., 1985) have attracted considerable attention. Inhibition
of experimental and spontaneous pulmonary metastasis in
C3H/He mice with CRT ( + ) cells, and dose-dependent mode
of this inhibition have been reported by colleagues in other
departments. (Ochiai et al., 1986; Masuyama et al., 1987).
Figure I shows the molecular structure of 4, 6-0-
Benzylidene-D-glucopyranose (BG), a glucoside derivative of
BA. BG is soluble enough in saline to be injected in-
travenously, unlike BA which has to be taken orally by the
patients in the form of P-cyclo-dextrin inclusion compound.
One remarkable feature common to BA and BG is the lack
of toxicity, either acute or chronic. According to the past
tests (Kaken in-house report, 1986), the LD% of BG in mice
and rats is more than 400 mg kg-' by intravenous injection,
more than 3,000 mg kg-' by oral, and more than
1,440 mg kg- by peritoneal administration. No significant
effect on Wistar rats (30 males and 30 females) was observed
during, or after, a 6-month peritoneal administration of a
maximum dose of 200 mg kg-' daily of BG, and similar
results have been observed in beagles injected intravenously
with 60 mg kg-' daily of BG for 6 months, except for a slight
loss ofappetite. No induction of anaphylaxis occurred due to
the peritoneal injection of three doses of 30 mg BG every
other day in 4 Hartley marmots. No effect on sper-
matogenesis was observed by histological examination after a
6-month test (in rats and beagles), nor on reproductive func-
tions (rats). Mutagencity tests on Salmonella typhimurium
strains and a strain of Escherichia coli were negative. BG
administered to rats was distributed mainly in kidney, and
40% of the dose was excreted within 24 h; the level of
hippuric acid accumulated in urine (that may suggest libera-
tion of BA from BG) reached a maximum 3 to 6 h after
administration. It is noteworthy that bone-marrow depres-
sion, gastrointestinal disturbances, and other adverse effects
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Figure 1 Molecular structure of BG.
almost inherent with the currently used anti-tumour agents
have never been observed for BA and BG, even when large
doses were used for considerable periods.
Favourable results of a clinical trial of BG in cancers of
various organs have been reported (Kochi et al., 1985), in-
cluding anti-tumour response in 55.3% of 65 patients, with
10.7% complete regression. The aim of the present study was
to confirm the clinical efficacy of BG on various types of
solid malignant carcinomas, as an extended Phase I study.
Patients and methods
A total of 24 patients with advanced stage carcinomas were
included in the present trial. The diagnoses of all cases were
confirmed by histological assessment from operation or
biopsy. They consisted of I I cases of primary lung cancer, 4
with metastatic lung cancer, 5 patients with gastric cancer,
and one patient each with cancer of the sigmoid colon, liver,
pancreas and prostate. The characteristics of the 20 male and
4 female cases are summarised in Table I. The average age of
this group was 63.6 years, ranging from 11 to 86-years-old.
The performance status of the patients was evaluated before
and after the treatment.
BG was a gift from Kaken Pharmaceutical Co, (Tokyo,
Japan), in vials each containing 1.2 g lyophilised BG (98%
4,6-0-benzylidene glucopyranose). Doses of 1.2 g BG dis-
solved in 100 ml saline (pH 4.5-6.5) were infused in-
travenously every morning and evening during the treatment
period. This dose, suggested by the manufacturer's research
group, was regarded as being considerably within the safety
limit, in view of the virtual lack of any toxicity suggested by
animal tests, but signs of any side effects were carefully
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Table I Patient characteristics
Evaluable number
Sex
Male
Female
Age
Range
Mean
Sites of tumour
Lung
Metastatic lung
Stomach
Sigmoid colon
Liver
Pancreas
Prostate
Performance status*
0
l
2
3
4
*pretreatment
24
20
4
11-86
63.6
11
4
5
1
l
5
3
10
5
monitored according to the WHO guidelines for toxicity. The
treatment was continued for two months, and was terminated
if no response was observed. The treatment was applied with
patients' consent after they were informed of the nature of
the trial. X-ray and endoscopic examinations were conducted
every month and computed tomography was carried out
when necessary for the assessment of the effect of treatment.
Complete blood counts, total protein, albumin, SGOT,
SGPT, LDH, alkaline phosphatase, CPK, blood urea nit-
rogen, creatinine, and uric acid and urinalysis were per-
formed every two weeks for the first month of treatment,
followed by monthly monitoring of the status of the patients.
Body weight and symptoms were also evaluated to appraise
the efficacy of therapy.
Results
Among the 24 patients treated, a complete response (CR)
according to the WHO criteria was noted in two cases; one
male patient with synchronous ipsilateral pleura, diaphragm
Table II List of patients in this series
Performance status survival Primary Metastatic Total doses Responding time
No. Patient Sex Age organ Histology site (s) before after Prior therapy ofBG (mg) Response site (s) (m)
I M.S M 69 lung s.c.c.(I) 3 1 (-) 216,000 PR 7 alive9
2 A.M M 50 " ad.sq.c2 spinal cord 4 4 lobectomy 254,400 PR spinal cord 6 death4
adrenal gland
liver
s.c.c ( ) 2
ad.c.3 (-) 3
ad.c () 0
ad.c brain 3
carcinoid (-) 0
ad.c ()
s.c.c brain
ad.c ()
s.c.c. kidney
reast inf.duct.c6 ipsilateral
lung and
pleura
idney clear c.c7 lung
mur osteosar- bilateral
coma lung
mur chondro- bilateral
sarcoma lung
mach ad.c multiple
lung etc
local recurrence,
liver, peritonitis
carcinomatosa
multiple
liver
multiple
liver
multiple
liver
moid bilateral
liver
iver hepatoma (-)
single
liver
multiple
bones, lung
4
2
3
3
4
0
0
4
4
3
3
3
0
2
3
3
liver
0
1
0
0
4
0
3
0
1 0
0
4
4
0
2
thoracotomy 160,800 PR
(-)
(-)
brain tumour
extirpation
(-)
(-)
(-)
(-)
lobectomy
(-)
nephrectomy
amputation
amputation
total
gastrectomy
gastrectomy
138,400
50,400
60,000
122,400
722,400
118,800
662,400
122,000
662,400
182,200
63,600
22,800
60,000
86,400
gastrectomy 748,800
657,600
358,800
67,200
301,200
252,400
415,200
MR
NC
PD
MR
PR
PD
PR
PD
CR
necrosis of
lung tumour
10 alive
9 alive
4 alive9
3 alive5
2 alive5
29 alive
7 death
17 alive
4 death
11 alive
PR metastatic 10 alive
lesion
PD 5 death
PD
PD
3 alive9
I death
PD necrosis of 3 death4
lung and liver
lesions
CR liver 20 alive
metastases
PR liver 21 alive
NC
PD
16 death
4 death
PR
MR
MR
10 death8
27 death
18 alive
M
M
M
F
F
M
M
M
M
M
73
86
66
71
46
69
68
42
68
70
3
4
S
6
7
8
9
10
11
12
13
14
15
16
17
K.S
N.K
O.J
l.Y
H.K
K.M
A.T
U.S
N.T
K.T
K.I
T.H
M.Y M
N.K M
K.A F
bi
M 65 ki
F 11 fe
fe
sto
52
51
59
M 74 18 T.S
19 W.A
20 H.S
21 T.K
22 I.T
23 T.T
24 T.T
M 70
M 68
M 76 sigi
M 78 Ii
M 65 pan
M 80 pro
creas ad.c
state "
1. s.c.c: squamous cell carcinoma, 2. ad.sq.c: adenosquamous cell carcinoma, 3. ad.c: adenocarcinoma, 4. autopsy, 5. operation, 6. inf. duct C:
infiltrating ductal carcinoma, 7. clearc.c: clear cell carcinoma, 8. myocardial infarction, 9. change to othertherapy, (Dept. ofSurg., Toyama Med. & Pharm., Univ., July, 1987).438 T. TATSUMURA et al.
and lung metastases due to breast cancer, and a patient with
metastatic liver lesions due to gastric cancer. A partial res-
ponse (PR) was noted in 8 of the 24 patients, while MR was
seen in 4 patients, yielding an overall response rate of 58.3%.
An anti-tumour response rate of 41.6% is obtained if only
CR and PR are considered. Ten of the 24 patients showed no
response (NC) to therapy, or had progressive disease (Table
II). At the start of treatment, the majority (18 of 24) of the
patients had a performance status of grade 2 or worse. As
shown in Table III, marked improvement of performance
status was noted in patients who showed an objective thera-
peutic response (CR and PR), and improvement in perform-
ance status was also noted among those patients with MR or
NC response. The mean survival time of the total cases at
completion of the trial was 10.3 months. The 2 patients who
had a CR anti-tumour response are still alive 11 and 20
months after the treatment (Figures 2 and 3).
Therapeutic assessment by histologic study was possible in
three of the 24 cases, apart from appraisal of the size of the
tumours by clinical methods. Of these three cases, two were
evaluated by postmortem studies, and one was studied by
examination of surgical specimens obtained through oper-
ation following BG treatment. Characteristic tissue response
to BG, i.e., massive necrosis of the tumour tissue, was found
but no apparent damage was found in the surrounding nor-
mal tissue.
No haematological, liver, renal or cardiac toxicity was
attributable to treatment, and no nausea, vomiting or other
adverse reactions were noted.
Discussion
Among 24 patients response was seen in 10, with 2 CR.
These results were comparable to those of Kochi et al.
(1985), and support the view that BG can be clinically useful
for the treatment of tumours. One of the interesting features
revealed in this study is the apparent lack of accompanying
toxicity of BG, at least with the size of dose used, which is
exceptional for anti-tumour agents and widens the future
potential use of this drug. Another is the specific necrotic
liquefaction of the tumour cells by this treatment, without
any damage to surrounding normal cells seen in two cases in
which histological assessment was feasible. This feature,
which might have also been present in the other cases, may
be a characterisitc of BG.
Watanuki et al. (1980, 1981) noted that benzaldehyde
selectively inhibited the uptake of nutrients into SV-40 trans-
formed cell lines, but not their normal counterparts. These
findings were also confirmed by other investigators (Takeuchi
et al., 1978; Ishida et al., 1983). The mechanism of the
anti-tumour action of BG is still unclear, except that it might
TableIII Improvementinperformancestatusnoted inpatientstreated
with BG
Therapeutic Performance status
response Pretreatment after Number ofcases(s)
CR 3 0 CR 3 1
4 1 2
3 1 2
PR 3 0 1
2 1
2 0 1
3 1 2 MR32
NC 3 1 1
be related to that of BA and is probably entirely different
from those of most anti-tumour agents, as suggested by the
observed tumour cell-specific necrosis. It is not even clear if
BG is actually a prodrug of BA, though this is suggested by
the increase in urine hippuric acid level.
Figure 2 Plan PA views of the metastatic lesions of the left
pleura (p), lung (+), diaphragm (+) and pericardium (>)
before the treatment with BG.
Figure 3 After a total of 662.4 g of BG has been administered, a
complete disapearance of all the tumours were observed.4, 6-0-BENZYLIDENE-D-GLUCOPYRANOSE 439
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